期刊文献+

Synthesis and Biological Evaluation of Entecavir 4'-Ester Derivatives

Synthesis and Biological Evaluation of Entecavir 4'-Ester Derivatives
原文传递
导出
摘要 Entecavir can significantly inhibit the replication of HBV-DNA, reduce the HBV-DNA level in blood se- rum. But suffering from low oral bioavailability, entecavir has low intestinal membrane permeability and poor meta- bolic stability. In this study, 12 different derivatives of entecavir 4'-ester were regioselectively synthesized and their apical-to-basolateral permeabilities across Caco-2 cells and HBV-DNA inhibitory efficacies were evaluated. Most of the compounds showed high permeabilities across Caco-2 cells compared with entecavir, compounds 5b and 5e also exhibited comparable anti-HBV activities with that of entecavir, especially. Entecavir can significantly inhibit the replication of HBV-DNA, reduce the HBV-DNA level in blood se- rum. But suffering from low oral bioavailability, entecavir has low intestinal membrane permeability and poor meta- bolic stability. In this study, 12 different derivatives of entecavir 4'-ester were regioselectively synthesized and their apical-to-basolateral permeabilities across Caco-2 cells and HBV-DNA inhibitory efficacies were evaluated. Most of the compounds showed high permeabilities across Caco-2 cells compared with entecavir, compounds 5b and 5e also exhibited comparable anti-HBV activities with that of entecavir, especially.
出处 《Chemical Research in Chinese Universities》 SCIE CAS CSCD 2014年第5期749-754,共6页 高等学校化学研究(英文版)
基金 Supported by the National Natural Science Foundation of China(No.51209024) and the Science and Technology Plan of Si- chuan Province, China(No.2010JY0122).
关键词 ENTECAVIR Anti-HBV activity Intestinal membrane permeability Entecavir Anti-HBV activity Intestinal membrane permeability
  • 相关文献

参考文献26

  • 1Shi C. C., Tjwa E. T., Biesta E J., Boonstra A., Xie Q., Janssen H. L., Woltman A. M., 1 Vir. Hepatitis, 2012, 19(2), 26.
  • 2Pothakamuri V. S., Sven E, Verena S., Jan G., Paraskevi E, Anna G., Birgit B.B., Antoaneta M., Jerzy J., Christoph B., Michael E M., Markus C., Heiner W., Hepatology, 2012, 55(3), 695.
  • 3Jensbukh M. D., Robert E., Lanford E D., Robert H., Purcell M. D., Hepatology, 2013, 58(5), 1533.
  • 4Rehermann B., Nascimbeni M., Nat. Rev. ImmunoL, 2005, 5(3), 215.
  • 5Fisicaro R, Valdatta C., Boni C., Massari M., Mori C., Zerbini C., Orlandini A., Sacchelli L., Missale G., Ferrari C., Hepatology, 2009, 58, 974.
  • 6Daniel G., Maximilian H., Robert T., Clin. Sci., 2013, 124, 77.
  • 7Han Q. J., Zhang C., Zhang J., Tian Z. G., Semin. Immunopathol, 2013, 35(1), 23.
  • 8Dienstag J. L., Perrillo R. E, Schiff E. R., Bartholomew M., Vicary C., Rubin M., N. Engl. J. Med., 1995, 333, 1657.
  • 9Cullen J. M., Li D. H., Brown C., Eisenberg E. J., Cundy K. C., Wolfe J., Toole J., Gibbs C., Antimicrob. Agents Chemother., 2001, 45(10), 2740.
  • 10Stevens R. C., Blum M. R., Rousseau F. S., Kearney B. P., Anderson E L., Kakuda T. N., Liehtenstein K. A., Clin. Infect. Dis., 2004, 39, 877.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部